Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 5/20 | 0.50 |
| ▸ | BCR | P11274 | 4/20 | 0.50 |
| ▸ | PRKCA | P17252 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739226 | 0.88 | PLK1 (0.64) | PLK1PIK3CAPIK3CGMEN1KMT2A | |
| SCHEMBL4733865 | 0.85 | MEN1 (0.60) | PLK1PIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL4735604 | 0.80 | PLK1 (1.00) | PLK1PIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL4732832 | 0.79 | PLK1 (0.74) | PLK1PIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL4737541 | 0.77 | PLK1 (0.61) | PLK1PIK3CGMEN1KMT2AABL1 | |
| SCHEMBL4734426 | 0.77 | PLK1 (0.80) | PLK1PIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL4733185 | 0.76 | PLK1 (0.79) | PLK1PIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL4733651 | 0.75 | PLK1 (0.84) | PLK1PIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL4735260 | 0.74 | PLK1 (0.68) | PLK1PIK3CGMEN1KMT2AABL1 | |
| SCHEMBL3864320 | 0.74 | ABL1 (0.76) | PLK1PIK3CAPIK3CBPIK3CGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| JP-2007500179-A | — | — | 2007-01-11 | — | — | JP | claimed |
| CN-1860104-A | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LTD (GB) | 2006-11-08 | — | — | CN | claimed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | claimed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| CN-1860104-A | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LTD (GB) | 2006-11-08 | — | — | CN | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | PLK1 1603/4885PIK3CA 780/4885PIK3CB 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.